The tweet was deleted by the author.
But we saved everything 🙂.
Ocugen, Inc. announced encouraging 12-month results from its Phase 2 trial of OCU410, a one-time gene therapy targeting geographic atrophy (GA).
Initial data indicate a measurable impact on both lesion growth and visual function, reinforcing OCU410's potential to shift the treatment paradigm for GA and serve unmet patient needs. The company continues to advance development efforts and will release further data as the study progresses.
Ocugen has previously accelerated development of modifier gene therapies to treat major blindness diseases, addressing rising concerns around eye health, according to a recent article. The company has also pledged support for Rare Disease Day and continues to advance gene therapies for rare inherited retinal conditions, as highlighted in a recent report. These efforts reflect Ocugen's continued focus on innovation in the treatment of retinal diseases.